Is Synageva BioPharma a Buy? Baker Bros. Thinks So
Is Synageva BioPharma a buy? Baker Bros. Advisors, a hedge fund managed by Julian and Felix Baker with a focus on biotechnology, increased its stake in Synageva BioPharma Corp (NASDAQ:GEVA) today.
Hedge Fund - Baker Bros. Advisors
News, Interviews, and Investor Letters
- First
- << Previous
- 71 - 76
This Metric Says You Are Smart to Sell Ariad Pharmaceuticals, Inc. (ARIA)
In the eyes of many investors, hedge funds are seen as overrated, old financial tools of a forgotten age.
Onyx Pharmaceuticals, Inc. (ONXX) Investors: Listen Up
In the 21st century investor’s toolkit, there are tons of metrics shareholders can use to track publicly traded companies.
Hedge Funds Are Crazy About BioMarin Pharmaceutical Inc. (BMRN)
In the financial world, there are dozens of gauges shareholders can use to analyze stocks. Two of the most under-the-radar are hedge fund and insider trading sentiment.
Baker Bros. Advisors Boosts Stake in Vanda Pharmaceuticals Inc. (VNDA)
In the hedge fund world, Julian Baker and Felix Baker’s Baker Bros. Advisors reported a purchase of 2,028,789 shares in Vanda Pharmaceuticals Inc.
Pharmacyclics, Inc. (PCYC), Genomic Health, Inc. (GHDX)...Mega-Hedge Fund Focusing on The Life Sciences
The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies with a small to medium sized market capitalization...
- First
- << Previous
- 71 - 76